FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 6,000 shares of FibroGen stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $47.38, for a total value of $284,280.00. Following the transaction, the director now owns 28,000 shares of the company’s stock, valued at approximately $1,326,640. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Kalevi Kurkijarvi also recently made the following trade(s):
- On Monday, December 18th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The shares were sold at an average price of $42.80, for a total value of $85,600.00.
- On Tuesday, December 12th, Kalevi Kurkijarvi sold 12,000 shares of FibroGen stock. The shares were sold at an average price of $44.45, for a total value of $533,400.00.
- On Friday, November 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The shares were sold at an average price of $46.65, for a total value of $93,300.00.
FibroGen Inc (NASDAQ FGEN) opened at $47.85 on Monday. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen Inc has a 52 week low of $21.05 and a 52 week high of $60.15. The firm has a market capitalization of $3,930.00, a PE ratio of -23.57 and a beta of 1.55.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.13). FibroGen had a negative net margin of 120.00% and a negative return on equity of 47.36%. research analysts forecast that FibroGen Inc will post -1.75 earnings per share for the current year.
Several institutional investors have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. increased its stake in shares of FibroGen by 8.4% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 361,564 shares of the biopharmaceutical company’s stock valued at $17,139,000 after purchasing an additional 27,904 shares in the last quarter. Bank of Montreal Can boosted its holdings in FibroGen by 2,097.2% in the 4th quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 3,041 shares during the last quarter. Iguana Healthcare Management LLC acquired a new stake in FibroGen in the 3rd quarter worth about $2,152,000. California Public Employees Retirement System boosted its holdings in FibroGen by 1.8% in the 3rd quarter. California Public Employees Retirement System now owns 94,900 shares of the biopharmaceutical company’s stock worth $5,106,000 after buying an additional 1,700 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in FibroGen in the 3rd quarter worth about $462,000. Hedge funds and other institutional investors own 57.23% of the company’s stock.
Several brokerages recently weighed in on FGEN. BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Mizuho restated a “hold” rating and issued a $61.00 price target on shares of FibroGen in a research note on Thursday, November 9th. One analyst has rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $65.67.
ILLEGAL ACTIVITY NOTICE: “FibroGen Inc (FGEN) Director Sells $284,280.00 in Stock” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/22/fibrogen-inc-fgen-director-sells-284280-00-in-stock.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.